Defence Therapeutics has appointed Ryan Simms, PhD, as Chief Operating Officer and Head of Radiopharmaceutical Programs to enhance its leadership and accelerate its radiopharmaceutical drug conjugate programs. Simms brings over 20 years of experience in targeted radiopharmaceuticals, having held key roles at Fusion Pharmaceuticals and other biotech firms. His expertise will help Defence select lead candidates and advance them through preclinical stages while establishing manufacturing frameworks. This move, along with recent leadership changes and a new office in a major Canadian radiopharmaceutical hub, positions Defence for growth in precision oncology therapeutics.
Nebius Group N.V. is rated a cautious Buy due to strong demand for AI infrastructure but significant challenges in execution and capital allocation. The company's success depends on quickly deploying capacity, financing growth with minimal dilution, ...
Circle has introduced Digital Asset-Backed Borrowing for eligible institutional customers, allowing them to deposit Bitcoin, mint cirBTC, and borrow USDC through third-party lending protocols like Morpho on Arc, with Aave expected to join later. This...
Grand Canyon Education (LOPE) shares have fallen 28% over the past year, mainly due to concerns about AI disruption. However, the company reported strong second-quarter 2026 results with broad enrollment growth, especially in its profitable hybrid se...
Elon Musk's social platform X now allows U.S. users to tap cashtags like $BTC or $TSLA to view live charts and initiate trades. Users are redirected to partner platforms such as Coinbase, Kraken, Gemini, Interactive Brokers, or Moomoo to complete tra...
Ondo Finance has introduced an in-kind conversion route allowing approved institutions to directly convert existing shares into Ondo Stocks tokens via Alpaca’s Instant Tokenization Network on Ethereum and BNB Chain. This new process eliminates the ne...
